New Long-Term Data from the CHRYSALIS Study Show Median Progression-Free Survival Not Reached After 33.6 Months of Follow Up with First-Line Use of RYBREVANT®▼ (amivantamab) and Lazertinib Combination Therapy in Patients with Treatment-Naïve EGFR-Mutated